[HTML][HTML] ARCHES: a randomized, phase III study of androgen deprivation therapy with enzalutamide or placebo in men with metastatic hormone-sensitive prostate …
AJ Armstrong, RZ Szmulewitz, DP Petrylak… - Journal of Clinical …, 2019 - ncbi.nlm.nih.gov
PURPOSE Enzalutamide, a potent androgen-receptor inhibitor, has demonstrated significant
benefits in metastatic and nonmetastatic castration-resistant prostate cancer. We evaluated …
benefits in metastatic and nonmetastatic castration-resistant prostate cancer. We evaluated …
[HTML][HTML] Glucocorticoid receptor activity contributes to resistance to androgen-targeted therapy in prostate cancer
…, DJ Vander Griend, SD Conzen, RZ Szmulewitz - Hormones and …, 2014 - Springer
Despite new treatments for castrate-resistant prostate cancer (CRPC), the prognosis of
patients with CRPC remains bleak due to acquired resistance to androgen receptor (AR)-directed …
patients with CRPC remains bleak due to acquired resistance to androgen receptor (AR)-directed …
[HTML][HTML] Prospective multicenter validation of androgen receptor splice variant 7 and hormone therapy resistance in high-risk castration-resistant prostate cancer: the …
…, P Giannakakou, RZ Szmulewitz… - Journal of Clinical …, 2019 - ncbi.nlm.nih.gov
PURPOSE Androgen receptor splice variant 7 (AR-V7) results in a truncated receptor,
which leads to ligand-independent constitutive activation that is not inhibited by anti-androgen …
which leads to ligand-independent constitutive activation that is not inhibited by anti-androgen …
[HTML][HTML] Improved survival with enzalutamide in patients with metastatic hormone-sensitive prostate cancer
…, AA Azad, T Iguchi, RZ Szmulewitz… - Journal of Clinical …, 2022 - ncbi.nlm.nih.gov
Enzalutamide in combination with androgen deprivation therapy (ADT) is approved for the
treatment of metastatic hormone-sensitive prostate cancer (mHSPC [also referred to as …
treatment of metastatic hormone-sensitive prostate cancer (mHSPC [also referred to as …
[HTML][HTML] Sox2 is an androgen receptor-repressed gene that promotes castration-resistant prostate cancer
…, EE Reyes, KB Otto, W Tom, GP Paner, RZ Szmulewitz… - PloS one, 2013 - journals.plos.org
Despite advances in detection and therapy, castration-resistant prostate cancer continues to
be a major clinical problem. The aberrant activity of stem cell pathways, and their regulation …
be a major clinical problem. The aberrant activity of stem cell pathways, and their regulation …
A phase II trial of the aurora kinase a inhibitor alisertib for patients with castration-resistant and neuroendocrine prostate cancer: efficacy and biomarkers
…, B Montgomery, C Hoimes, RZ Szmulewitz… - Clinical Cancer …, 2019 - AACR
Purpose: Neuroendocrine prostate cancer (NEPC) is an aggressive variant of prostate cancer
that may develop de novo or as a mechanism of treatment resistance. N-myc is capable of …
that may develop de novo or as a mechanism of treatment resistance. N-myc is capable of …
[HTML][HTML] Prospective international randomized phase II study of low-dose abiraterone with food versus standard dose abiraterone in castration-resistant prostate …
RZ Szmulewitz, CJ Peer, A Ibraheem… - Journal of Clinical …, 2018 - ncbi.nlm.nih.gov
Purpose Abiraterone acetate (AA) is a standard of care for metastatic castration-resistant
prostate cancer (CRPC). Despite a large food effect, AA was administered under fasting …
prostate cancer (CRPC). Despite a large food effect, AA was administered under fasting …
First-in-human study of mivebresib (ABBV-075), an oral pan-inhibitor of bromodomain and extra terminal proteins, in patients with relapsed/refractory solid tumors
…, JC Sachdev, M Barve, P LoRusso, R Szmulewitz… - Clinical Cancer …, 2019 - AACR
Purpose: Bromodomain and extraterminal (BET) proteins play important roles in transcriptional
regulation relevant to cancer pathogenesis, and therapeutic targeting/inhibition of BET …
regulation relevant to cancer pathogenesis, and therapeutic targeting/inhibition of BET …
[HTML][HTML] Acquired resistance to the second-generation androgen receptor antagonist enzalutamide in castration-resistant prostate cancer
Enzalutamide (MDV3100) is a second generation Androgen Receptor (AR) antagonist with
proven efficacy in the treatment of castration resistant prostate cancer (CRPC). The majority …
proven efficacy in the treatment of castration resistant prostate cancer (CRPC). The majority …
[HTML][HTML] Cancer and Leukemia Group B 90203 (Alliance): radical prostatectomy with or without neoadjuvant chemohormonal therapy in localized, high-risk prostate …
…, CP Evans, SK Clinton, RZ Szmulewitz… - Journal of Clinical …, 2020 - ncbi.nlm.nih.gov
PURPOSE Radical prostatectomy (RP) alone is often inadequate in curing men with clinically
localized, high-risk prostate cancer (PC). We hypothesized that chemohormonal therapy (…
localized, high-risk prostate cancer (PC). We hypothesized that chemohormonal therapy (…